Relevance of Abnormal KCNN1 Expression and Osmotic Hypersensitivity in Ewing Sarcoma

Fuest, Sebastian; Post, Christoph; Balbach, Sebastian T.; Jabar, Susanne; Neumann, Ilka; Schimmelpfennig, Sandra; Sargin, Sarah; Nass, Elke; Budde, Thomas; Kailayangiri, Sareetha; Altvater, Bianca; Ranft, Andreas; Hartmann, Wolfgang; Dirksen, Uta; Rossig, Claudia; Schwab, Albrecht; Pethő, Zoltán (2022)

In: Cancers, 14(19), 4819.

Forschungsartikel (Zeitschrift)

ANALYSIS OF THE VALUE OF HIGH DOSE CHEMOTHERAPY IN RELAPSED EWING SARCOMA PATIENTS AND COMPARISON OF HIGH DOSE CHEMOTHERAPY REGIMENS BUSULFAN-MELPHALAN VERSUS TREOSULFAN-MELPHALAN FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION

Rasper M, Jabar S, Amler S, Ranft A, Juergens H, Dirksen U (2012)

In: Pediatric Blood and Cancer, 59(6).

Forschungsartikel (Zeitschrift)

WALKING ABILITY OF PAEDIATRIC PATIENTS AFTER SURGICAL TREATMENT OF A MALIGNANT BONE TUMOR IN THE LOWER LIMB. EFFECT OF FOLLOW-UP DURATION

Winter C, Mueller C, Brandes M, Hardes J, Ranft A, Hoffmann C, Boos J, Gosheger G, Rosenbaum D, Juergens H, Dirksen U (2011)

In: Pediatric Blood and Cancer, 57(5).

Forschungsartikel (Zeitschrift)

RANDOMISED COMPARISON OF CYCLOPHOSPHAMIDE VERSUS IFOSFAMIDE CONTAINING ADJUVANT CHEMOTHERAPY (CTX) IN STANDARD RISK (SR) EWING SARCOMA (ES) PATIENTS: RESULTS OF THE EURO EWING-99 TRIAL

Dirksen U, LeDeley MC, Whelan J, Paulussen M, Oberlin O, Lewis I, Ranft A, Michon J, Ladenstein R, Brennan B, Perinne MB, Van den Berg H, Hjorth L, Wheatley K, Douglas C, Van Glabbeke M, Judson I, Craft A, Jurgens H (2011)

In: Pediatric Blood and Cancer, 57(5).

Forschungsartikel (Zeitschrift)

Retrospective analysis of treatment-related toxicities and outcome in high-risk Ewing sarcoma patients receiving PO or IV busulfan-based high-dose chemotherapy with autologous stem cell transplantation

Ranft A, Jabar S, Dirksen U, Ehlert K, Boos J, Bader P, Ladenstein R, Jurgens H (2011)

In: Bone Marrow Transplantation, 46 1.

Forschungsartikel (Zeitschrift)

Publikationen

Kontakt

Top-Links

Relevance of Abnormal KCNN1 Expression and Osmotic Hypersensitivity in Ewing Sarcoma Fuest, Sebastian; Post, Christoph; Balbach, Sebastian T.; Jabar, Susanne; Neumann, Ilka; Schimmelpfennig, Sandra; Sargin, Sarah; Nass, Elke; Budde, Thomas; Kailayangiri, Sareetha; Altvater, Bianca; Ranft, Andreas; Hartmann, Wolfgang; Dirksen, Uta; Rossig, Claudia; Schwab, Albrecht; Pethő, Zoltán (2022) In: Cancers, 14(19), 4819. Forschungsartikel (Zeitschrift)
Stenotrophomonas maltophilia Infections in Pediatric Patients - Experience at a European Center for Pediatric Hematology and Oncology Zöllner SK, Kampmeier S, Froböse NJ, Herbrüggen H, Masjosthusmann K, Heuvel A, Reicherts C, Ranft A, Groll AH (2021) In: Frontiers in Oncology, 11. Forschungsartikel (Zeitschrift)
ANALYSIS OF THE VALUE OF HIGH DOSE CHEMOTHERAPY IN RELAPSED EWING SARCOMA PATIENTS AND COMPARISON OF HIGH DOSE CHEMOTHERAPY REGIMENS BUSULFAN-MELPHALAN VERSUS TREOSULFAN-MELPHALAN FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION Rasper M, Jabar S, Amler S, Ranft A, Juergens H, Dirksen U (2012) In: Pediatric Blood and Cancer, 59(6). Forschungsartikel (Zeitschrift)
TREATMENT-RELATED TOXICITIES AND OUTCOME IN EWING SARCOMA PATIENTS RECEIVING PER OS (PO) OR IV BUSULFAN-BASED HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION Dirksen U, Jabar S, Boos J, Bader P, Ladenstein R, Jurgens H, Ranft A (2011) In: Pediatric Blood and Cancer, 57(5). Forschungsartikel (Zeitschrift)
WALKING ABILITY OF PAEDIATRIC PATIENTS AFTER SURGICAL TREATMENT OF A MALIGNANT BONE TUMOR IN THE LOWER LIMB. EFFECT OF FOLLOW-UP DURATION Winter C, Mueller C, Brandes M, Hardes J, Ranft A, Hoffmann C, Boos J, Gosheger G, Rosenbaum D, Juergens H, Dirksen U (2011) In: Pediatric Blood and Cancer, 57(5). Forschungsartikel (Zeitschrift)
HOW TO MEASURE LONG-TERM OUTCOME OF EWING SARCOMA TREATMENT! Ranft A, Hoffmann C, Winter C, Dirksen U, Rosenbaum D, Juergens H (2011) In: Pediatric Blood and Cancer, 57(5). Forschungsartikel (Zeitschrift)
RANDOMISED COMPARISON OF CYCLOPHOSPHAMIDE VERSUS IFOSFAMIDE CONTAINING ADJUVANT CHEMOTHERAPY (CTX) IN STANDARD RISK (SR) EWING SARCOMA (ES) PATIENTS: RESULTS OF THE EURO EWING-99 TRIAL Dirksen U, LeDeley MC, Whelan J, Paulussen M, Oberlin O, Lewis I, Ranft A, Michon J, Ladenstein R, Brennan B, Perinne MB, Van den Berg H, Hjorth L, Wheatley K, Douglas C, Van Glabbeke M, Judson I, Craft A, Jurgens H (2011) In: Pediatric Blood and Cancer, 57(5). Forschungsartikel (Zeitschrift)
Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Stahl M, Ranft A, Paulussen M, Bölling T, Vieth V, Bielack S, Görtitz I, Braun-Munzinger G, Hardes J, Jürgens H, Dirksen U (2011) In: Pediatric Blood and Cancer, 57(4). Forschungsartikel (Zeitschrift)
Retrospective analysis of treatment-related toxicities and outcome in high-risk Ewing sarcoma patients receiving PO or IV busulfan-based high-dose chemotherapy with autologous stem cell transplantation Ranft A, Jabar S, Dirksen U, Ehlert K, Boos J, Bader P, Ladenstein R, Jurgens H (2011) In: Bone Marrow Transplantation, 46 1. Forschungsartikel (Zeitschrift)
The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Haeusler J, Ranft A, Boelling T, Gosheger G, Braun-Munzinger G, Vieth V, Burdach S, van den Berg H, Juergens H, Dirksen U (2010) In: Cancer, 116(2). Forschungsartikel (Zeitschrift)